ProMetic Life Sciences Inc. (TSE:PLI) received a C$5.00 target price from investment analysts at Scotiabank in a note issued to investors on Wednesday. The firm presently has a an “outperform” rating on the stock. Scotiabank’s price target indicates a potential upside of 81.82% from the company’s previous close.

Several other brokerages have also issued reports on PLI. Bloom Burton reiterated a “hold” rating on shares of ProMetic Life Sciences in a research report on Thursday, October 13th. Royal Bank Of Canada restated an “outperform” rating and set a C$4.70 price target on shares of ProMetic Life Sciences in a research report on Wednesday. TD Securities restated a “speculative buy” rating and set a C$4.50 price target on shares of ProMetic Life Sciences in a research report on Thursday, October 27th. Finally, CIBC lowered their price target on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Shares of ProMetic Life Sciences (TSE:PLI) traded down 1.82% during trading on Wednesday, reaching $2.70. 2,282,439 shares of the company’s stock were exchanged. The stock’s market cap is $1.63 billion. ProMetic Life Sciences has a 12-month low of $1.88 and a 12-month high of $3.62. The company has a 50 day moving average of $2.90 and a 200 day moving average of $2.94.

ProMetic Life Sciences Company Profile

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.